Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes
| dc.contributor.author | Florentin, M. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.contributor.author | Mikhailidis, D. P. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T18:51:25Z | |
| dc.date.available | 2015-11-24T18:51:25Z | |
| dc.identifier.issn | 1744-7666 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/18257 | |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Blood Pressure/drug effects | en |
| dc.subject | Child | en |
| dc.subject | Clinical Trials as Topic | en |
| dc.subject | Diabetes Mellitus, Type 2/*drug therapy | en |
| dc.subject | Dipeptidyl-Peptidase IV Inhibitors/therapeutic use | en |
| dc.subject | Drug Interactions | en |
| dc.subject | Drug Therapy, Combination | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use | en |
| dc.subject | Lipids/blood | en |
| dc.subject | Male | en |
| dc.subject | Pregnancy | en |
| dc.subject | Pyrazines/administration & dosage/adverse effects/*therapeutic use | en |
| dc.subject | Triazoles/administration & dosage/adverse effects/*therapeutic use | en |
| dc.title | Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes | en |
| heal.abstract | BACKGROUND: Sitagliptin is a novel agent for the treatment of type 2 diabetes either as monotherapy or in combination with metformin or a thiazolidinedione. OBJECTIVE: To review the efficacy and safety of sitagliptin in clinical trials and comment on drug interactions and safety issues arising from its use. METHODS: Relevant articles were identified through a PubMed search (up to May 2008). RESULTS/CONCLUSIONS: Sitagliptin either used alone or in combination with other hypoglycemic agents has a favorable glucose-lowering effect and safety profile. It has been associated with few side effects, mainly involving the gastrointestinal system and with a low incidence of hypoglycemia, while it generally demonstrated a neutral effect on body weight. Sitagliptin is a safe alternative or complementary option for patients with type 2 diabetes who do not reach the recommended glycosylated hemoglobin level with lifestyle interventions and/or current oral antidiabetic agents. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.primary | 10.1517/14656566.9.10.1705 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/18570604 | - |
| heal.identifier.secondary | http://informahealthcare.com/doi/abs/10.1517/14656566.9.10.1705 | - |
| heal.journalName | Expert Opin Pharmacother | en |
| heal.journalType | peer-reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 2008 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: